Zenas Biopharma Common Etf Price Prediction
| ZBIO Etf | USD 15.20 1.41 8.49% |
Momentum 49
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.73) | EPS Estimate Current Year (5.34) | EPS Estimate Next Year (4.40) | Wall Street Target Price 43.5714 | EPS Estimate Current Quarter (0.85) |
Using Zenas BioPharma hype-based prediction, you can estimate the value of Zenas BioPharma Common from the perspective of Zenas BioPharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Zenas BioPharma using Zenas BioPharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Zenas using crowd psychology based on the activity and movement of Zenas BioPharma's stock price.
Zenas BioPharma Implied Volatility | 1.5 |
Zenas BioPharma's implied volatility exposes the market's sentiment of Zenas BioPharma Common stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Zenas BioPharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Zenas BioPharma stock will not fluctuate a lot when Zenas BioPharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Zenas BioPharma to buy its etf at a price that has no basis in reality. In that case, they are not buying Zenas because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell etfs at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Zenas BioPharma after-hype prediction price | USD 13.49 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as etf price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Zenas contract
Based on the Rule 16, the options market is currently suggesting that Zenas BioPharma Common will have an average daily up or down price movement of about 0.0938% per day over the life of the 2026-02-20 option contract. With Zenas BioPharma trading at USD 15.2, that is roughly USD 0.0143 . If you think that the market is fully incorporating Zenas BioPharma's daily price movement you should consider acquiring Zenas BioPharma Common options at the current volatility level of 1.5%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Zenas BioPharma Basic Forecasting Models to cross-verify your projections. Zenas BioPharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Zenas BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zenas BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Etf prices, such as prices of Zenas BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Zenas BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Zenas BioPharma's etf value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zenas BioPharma's historical news coverage. Zenas BioPharma's after-hype downside and upside margins for the prediction period are 3.69 and 23.29, respectively. We have considered Zenas BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Zenas BioPharma is slightly risky at this time. Analysis and calculation of next after-hype price of Zenas BioPharma Common is based on 3 months time horizon.
Zenas BioPharma Etf Price Prediction Analysis
Have you ever been surprised when a price of a ETF such as Zenas BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zenas BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Etf price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zenas BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.33 | 9.83 | 2.63 | 0.08 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
15.20 | 13.49 | 7.67 |
|
Zenas BioPharma Hype Timeline
Zenas BioPharma Common is at this time traded for 15.20. The entity has historical hype elasticity of -2.63, and average elasticity to hype of competition of 0.08. Zenas is forecasted to decline in value after the next headline, with the price expected to drop to 13.49. The average volatility of media hype impact on the company price is about 123.18%. The price decrease on the next news is expected to be -7.67%, whereas the daily expected return is at this time at -0.33%. The volatility of related hype on Zenas BioPharma is about 3885.38%, with the expected price after the next announcement by competition of 15.28. About 26.0% of the company outstanding shares are owned by insiders. The company recorded earning per share (EPS) of 13.67. Zenas BioPharma Common had 1:2 split on the 24th of May 2018. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Zenas BioPharma Basic Forecasting Models to cross-verify your projections.Zenas BioPharma Related Hype Analysis
Having access to credible news sources related to Zenas BioPharma's direct competition is more important than ever and may enhance your ability to predict Zenas BioPharma's future price movements. Getting to know how Zenas BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zenas BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| UPB | Upstream Bio | (0.07) | 10 per month | 3.30 | 0.12 | 7.87 | (4.60) | 24.37 | |
| NTLA | Intellia Therapeutics | 0.83 | 10 per month | 0.00 | (0.1) | 11.23 | (8.86) | 61.94 | |
| SNDX | Syndax Pharmaceuticals | (0.29) | 11 per month | 2.46 | 0.1 | 8.88 | (5.07) | 18.09 | |
| WVE | Wave Life Sciences | (0.01) | 10 per month | 4.13 | 0.11 | 11.43 | (8.08) | 164.47 | |
| RLAY | Relay Therapeutics | 0.28 | 10 per month | 3.04 | 0.13 | 9.62 | (5.31) | 27.25 | |
| NVAX | Novavax | (0.21) | 11 per month | 0.00 | (0.16) | 4.02 | (4.83) | 14.35 | |
| AMLX | Amylyx Pharmaceuticals | (0.43) | 10 per month | 0.00 | (0.1) | 7.34 | (5.24) | 17.17 | |
| ORIC | Oric Pharmaceuticals | (0.66) | 8 per month | 0.00 | (0.13) | 4.48 | (4.48) | 34.41 | |
| TRVI | Trevi Therapeutics | 0.05 | 8 per month | 2.70 | 0.07 | 5.99 | (4.46) | 24.05 | |
| INBX | Inhibrx Biosciences | 3.04 | 9 per month | 4.11 | 0.13 | 7.03 | (7.23) | 112.80 |
Zenas BioPharma Additional Predictive Modules
Most predictive techniques to examine Zenas price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zenas using various technical indicators. When you analyze Zenas charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Zenas BioPharma Predictive Indicators
The successful prediction of Zenas BioPharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Zenas BioPharma Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Zenas BioPharma based on analysis of Zenas BioPharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Zenas BioPharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Zenas BioPharma's related companies.
Story Coverage note for Zenas BioPharma
The number of cover stories for Zenas BioPharma depends on current market conditions and Zenas BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Zenas BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Zenas BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Zenas BioPharma Short Properties
Zenas BioPharma's future price predictability will typically decrease when Zenas BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Zenas BioPharma Common often depends not only on the future outlook of the potential Zenas BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zenas BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.8 M | |
| Cash And Short Term Investments | 350.8 M |
Other Information on Investing in Zenas Etf
Zenas BioPharma financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma security.